CO-ARROW-ELECTRONICS
28.5.2024 17:01:30 CEST | Business Wire | Press release
Global technology provider Arrow Electronics and SiMa.ai, the software centric, embedded edge machine learning system-on-chip company, have entered into a strategic collaboration, enabling Arrow to distribute SiMa.ai products in the EMEA region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240528873376/en/
SiMa.ai’s Machine Learning System-on-Chip MLSoC (Photo: Business Wire)
SiMa.ai delivers one platform for all edge AI that scales with customers as their AI/ML projects evolve, from computer vision, to transformers to multimodal generative AI. The SiMa.ai MLSoC (Machine Learning System on Chip) enables full pipeline deployment of complete real-world workloads as a standalone edge-based system, with high performance and power efficiency.
SiMa.ai’s MLSoC works seamlessly with Palette Software to support customers across multiple verticals such as industrial manufacturing, retail, aerospace, defense, agriculture, and healthcare, with increased compute capabilities, while maximizing efficiency by delivering the highest frames per second per watt (FPS/W) performance in the edge AI/ML market.
With this agreement, Arrow and SiMa.ai will jointly market SiMa.ai’s offerings and Arrow will serve as the region’s exclusive distributor for the SiMa.ai MLSoC, SiMa.ai Palette Software and SiMa.ai Development Kits.
Margit Tischler, vice president of engineering in EMEA for Arrow, said, “At Arrow, we recognise the importance of artificial intelligence at the edge. SiMa.ai extends our AI line card, allowing us to offer our customers a solution tailored to their specific AI needs.”
“We are pleased to enter this distribution agreement with Arrow, which will speed access for customers throughout Europe and the Middle East to SiMa.ai’s one platform for all edge AI — and will support customers as their AI/ML journeys evolve — from computer vision to transformers to multimodal generative AI,” said Elizabeth Samara-Rubio, chief business officer, SiMa.ai. “This agreement with Arrow will help SiMa.ai scale further to meet rising customer demand as organizations increasingly need a partner to help them deploy and scale AI/ML workloads at the edge.”
Arrow will showcase SiMa.ai in its booth (at Stand J1) at Hardware Pioneers Max in London from 28 to 29 May, 2024. In addition, SiMa.ai will be participating in a talk with Arrow at Hardware Pioneers Max titled, “Accelerate the Entire Vision Pipeline,” which will explore the practical roadmap of machine learning and AI in key end applications on 29.5.24 in Conference Room 1, from 10:40 - 11:10.
For more information on how SiMa.ai can help accelerate edge ML projects, prospective customers can register for the Arrow webinar featuring SiMa.ai on 10th June, 2024 by clicking here or book an AI Consultation with Arrow Experts.
About Arrow Electronics:
Arrow Electronics guides innovation forward for thousands of leading technology manufacturers and service providers. With 2023 sales of $33 billion, Arrow develops technology solutions that help improve business and daily life. Learn more at arrow.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240528873376/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release
- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p
Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere
Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release
Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta
Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release
We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi
Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release
Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom